You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》石藥集團(01093.HK)首季純利14.72億元人民幣升26.9%
阿思達克 05-24 12:07
石藥集團(01093.HK)公布截至今年3月底止首季業績,營業額67.34億元人民幣(下同),按年升9.9%。純利14.72億元,按年升26.9%;每股盈利12.29分。

撇除去年同期出售附屬公司收益,今年首季基礎溢利14.72億元,按年增63.3%。

期內成藥業務方面錄得銷售收入54.8億元,較去年同期增加9.1%,實現穩定的增長。原料產品業務方面,受惠產品價格上升,首季維生素C產品於本期錄得銷售收入5.24億元,較去年同期增加22.9%。抗生素及其它產品的銷售收入亦因銷量上升增加31%至3.89億元。另外,功能食品及其它業務方面,受銷量下跌影響期內銷售收入3.41億元,較去年同期減少10.4%。

首季集團研發費用達6.91億元,按年增加21.7%,約佔成藥業務收入的12.6%。目前在研項目約300個,其中小分子創新藥40餘項、大分子創新藥40餘項,新型製劑20餘項,主要聚焦於腫瘤、自身免疫、精神神經、消化和代謝、心腦血管系統及抗感染治療領域。目前有30個產品處於藥品註冊審評待批階段,39個產品正在開展臨床試驗(包括31個創新藥以及8個新型製劑),以及5個產品待批臨床批件。

未來三年,集團預計將上市新產品60餘個,其中預計市場空間超過10億元的重磅品種將不少於15個,而納米技術平臺研發的多西他賽白蛋白納米粒、紫杉醇白蛋白納米粒(速溶)等產品,都是具有全球專利及極具市場價值的重磅產品。

集團現正積極物色收購及合作的機會,以加強產品管線及充分利用集團的銷售平臺。(el/u) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account